Empowering Bioanalytical Research with Cutting-Edge Technology
May 8, 2025

At Pharmidex, we are proud to contribute to scientific innovation through robust and reliable bioanalytical support from early discovery to regulated studies.

For over eight years, we've partnered with Shimadzu, using their LCMS-8060 and LC-2050 systems to deliver high-quality, data-driven results tailored to diverse client needs. Their instruments have played a key role in advancing our bioanalytical capabilities and supporting the success of our collaborative projects.

Our Head of Operations, Ash Alavijeh, recently shared insights from our long-standing collaboration as part of Shimadzu’s 150th anniversary testimonial series. We are honored to be part of their journey and look forward to continuing this partnership built on shared values of precision, reliability, and innovation.

👉 Read more stories from the Shimadzu global community here.

Shimazdu UK Team

#Pharmidex #Bioanalysis #LCMS #TranslationalScience #InnovationInPartnership

May 7, 2026
We are delighted to announce and congratulate Ash Alavijeh on his appointment as Chief Operating Officer at Pharmidex . Ash has been an integral part of Pharmidex’s journey, bringing strong leadership, strategic vision and a deep commitment to advancing our capabilities in drug discovery and development. In his new role as COO, he will play a key part in driving operational excellence and supporting the continued growth of the company. This appointment reflects both Ash’s contributions to date and our confidence in his leadership as we continue to expand and evolve. Please join us in congratulating Ash on this well-deserved achievement.
May 5, 2026
Asthma affects over 260 million people worldwide and remains a significant unmet medical need. At Pharmidex , we are proud to support the development of next-generation respiratory therapies through: In vivo respiratory disease models Whole Body Plethysmography (WBP) for functional readouts Integrated PK/PD and bioanalysis Our focus is simple: generate high-quality data that enables confident decision-making and accelerates progress for patients. Because behind every dataset is a patient waiting to breathe easier.
May 1, 2026
Early-stage innovators based in Scotland have access to a significant opportunity to advance their programs toward ProofOfConcept, with an additional £2.85M fund from the Scottish Government aimed at supporting early development and enabling further investment. 🗓️ Deadline: 8th May At Pharmidex , we work alongside our partners to generate robust, translational data that supports confident decision-making across early discovery and preclinical development. Our capabilities include: TargetExpression ModeOfActionStudies TargetEngagement HitIdentification ADME and PK profiling If you are preparing an application and require scientific input or timely quotations, we would be pleased to support your programme. 🔗 https://lnkd.in/eZ6vVjgN
More Posts